AU2002322295C1 - Spherical protein particles and methods of making and using them - Google Patents

Spherical protein particles and methods of making and using them Download PDF

Info

Publication number
AU2002322295C1
AU2002322295C1 AU2002322295A AU2002322295A AU2002322295C1 AU 2002322295 C1 AU2002322295 C1 AU 2002322295C1 AU 2002322295 A AU2002322295 A AU 2002322295A AU 2002322295 A AU2002322295 A AU 2002322295A AU 2002322295 C1 AU2002322295 C1 AU 2002322295C1
Authority
AU
Australia
Prior art keywords
protein
antibody
spps
crystalline
antigens
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2002322295A
Other languages
English (en)
Other versions
AU2002322295B2 (en
AU2002322295A1 (en
Inventor
Mikhail Chamachkine
Chandrika P. Govardhan
Chu W. Jung
Nazer Khalaf
Kirill Yakovlevsky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Altus Biologics Inc
Original Assignee
Altus Biologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altus Biologics Inc filed Critical Altus Biologics Inc
Publication of AU2002322295A1 publication Critical patent/AU2002322295A1/en
Assigned to ALTUS PHARMACEUTICALS INC. reassignment ALTUS PHARMACEUTICALS INC. Amend patent request/document other than specification (104) Assignors: ALTUS BIOLOGICS INC
Publication of AU2002322295B2 publication Critical patent/AU2002322295B2/en
Application granted granted Critical
Publication of AU2002322295C1 publication Critical patent/AU2002322295C1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C30—CRYSTAL GROWTH
    • C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B29/00—Single crystals or homogeneous polycrystalline material with defined structure characterised by the material or by their shape
    • C30B29/54—Organic compounds
    • C30B29/58—Macromolecular compounds
    • C—CHEMISTRY; METALLURGY
    • C30—CRYSTAL GROWTH
    • C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B29/00—Single crystals or homogeneous polycrystalline material with defined structure characterised by the material or by their shape
    • C30B29/60—Single crystals or homogeneous polycrystalline material with defined structure characterised by the material or by their shape characterised by shape
    • C—CHEMISTRY; METALLURGY
    • C30—CRYSTAL GROWTH
    • C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B7/00—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions
    • C30B7/02—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions by evaporation of the solvent
    • C30B7/06—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions by evaporation of the solvent using non-aqueous solvents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Materials Engineering (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nanotechnology (AREA)
  • Metallurgy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Optics & Photonics (AREA)
  • Medical Informatics (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
AU2002322295A 2001-06-21 2002-06-21 Spherical protein particles and methods of making and using them Ceased AU2002322295C1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29998901P 2001-06-21 2001-06-21
US60/299,989 2001-06-21
PCT/US2002/019870 WO2003000014A2 (en) 2001-06-21 2002-06-21 Spherical protein particles and methods of making and using them

Publications (3)

Publication Number Publication Date
AU2002322295A1 AU2002322295A1 (en) 2003-06-19
AU2002322295B2 AU2002322295B2 (en) 2008-07-03
AU2002322295C1 true AU2002322295C1 (en) 2008-12-18

Family

ID=23157185

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002322295A Ceased AU2002322295C1 (en) 2001-06-21 2002-06-21 Spherical protein particles and methods of making and using them

Country Status (8)

Country Link
US (2) US7998477B2 (https=)
EP (1) EP1492554B1 (https=)
JP (1) JP2005500304A (https=)
AU (1) AU2002322295C1 (https=)
CA (1) CA2451185A1 (https=)
IL (1) IL159475A0 (https=)
NZ (1) NZ530700A (https=)
WO (1) WO2003000014A2 (https=)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ526720A (en) * 2000-12-28 2007-11-30 Altus Pharmaceuticals Inc Crystallisation of whole antibodies or fragments thereof, on a large scale and a process allowing an alternative route for delivery of therapeutic antibodies
CA2451185A1 (en) 2001-06-21 2003-01-03 Altus Biologics, Inc. Spherical protein particles and methods of making and using them
JP4161101B2 (ja) * 2002-06-21 2008-10-08 独立行政法人 日本原子力研究開発機構 生体高分子の結晶育成装置
RU2426590C2 (ru) 2003-07-18 2011-08-20 Бакстер Интернэшнл Инк. Способы изготовления, применение и композиции небольших сферических частиц, приготовленных регулируемым фазовым разделением
JP2005241389A (ja) * 2004-02-25 2005-09-08 Ochiyanomizu Jiyoshi Univ 蛍光標識糖鎖の特異的固定化試薬および固定化方法
US8333995B2 (en) 2004-05-12 2012-12-18 Baxter International, Inc. Protein microspheres having injectable properties at high concentrations
DK2072040T3 (da) 2004-05-12 2013-07-29 Baxter Healthcare Sa Terapeutisk anvendelse af nukleinsyremikrokugler
US8728525B2 (en) 2004-05-12 2014-05-20 Baxter International Inc. Protein microspheres retaining pharmacokinetic and pharmacodynamic properties
WO2005112885A2 (en) 2004-05-12 2005-12-01 Baxter International Inc. Oligonucleotide-containing microspheres, their use for the manufacture of a medicament for treating diabetes type 1
JP5553963B2 (ja) 2004-10-22 2014-07-23 アムジエン・インコーポレーテツド 組換え抗体をリフォールディングする方法
ES2390354T3 (es) * 2005-07-22 2012-11-12 Amgen, Inc Liofilizados de proteínas concentrados, procedimientos y usos
DK1948259T3 (en) * 2005-10-26 2017-04-10 Genesis Tech Ltd ACELLULAR BIOabsorbable Tissue Regeneration Matrices Produced by Incubation of ACELLULAR BLOOD PRODUCTS
JP5147699B2 (ja) * 2005-12-20 2013-02-20 富士フイルム株式会社 タンパク質ナノ粒子およびその使用
CN101415395B (zh) 2006-03-29 2012-02-08 富士胶片株式会社 酪蛋白纳米粒子
JP5118139B2 (ja) 2006-08-04 2013-01-16 バクスター・インターナショナル・インコーポレイテッド 新規発症自己免疫性糖尿病を予防および／または逆転させるためのマイクロスフィアに基づく組成物
US20080299182A1 (en) * 2007-03-01 2008-12-04 Shuyuan Zhang Methods and formulations for topical gene therapy
CN101686939B (zh) 2007-04-17 2013-03-27 巴克斯特国际公司 用于肺部投送的核酸微粒
JP2008285432A (ja) 2007-05-16 2008-11-27 Fujifilm Corp 皮膚外用剤
EP2170283B1 (en) 2007-06-22 2019-01-09 Board of Regents, The University of Texas System Formation of stable submicron peptide or protein particles by thin film freezing
WO2009005709A1 (en) * 2007-06-28 2009-01-08 Surmodics, Inc. Polypeptide microparticles
WO2009005718A1 (en) * 2007-06-28 2009-01-08 Surmodics, Inc. Polypeptide microparticles having sustained release characteristics, methods and uses
KR100845009B1 (ko) * 2007-08-07 2008-07-08 한국생명공학연구원 전하를 띠는 물질이 고착된 다공성 고분자 입자 및 그제조방법
JP2012501965A (ja) 2008-06-16 2012-01-26 バインド バイオサイエンシズ インコーポレイテッド 薬剤を装填したポリマーナノ粒子及びその製造方法と使用方法
ES2721850T3 (es) 2008-06-16 2019-08-05 Pfizer Nanopartículas poliméricas terapéuticas que comprenden alcaloides vinca y procedimientos de fabricación y uso de las mismas
US8613951B2 (en) * 2008-06-16 2013-12-24 Bind Therapeutics, Inc. Therapeutic polymeric nanoparticles with mTor inhibitors and methods of making and using same
US8323685B2 (en) * 2008-08-20 2012-12-04 Baxter International Inc. Methods of processing compositions containing microparticles
US8367427B2 (en) 2008-08-20 2013-02-05 Baxter International Inc. Methods of processing compositions containing microparticles
US8323615B2 (en) 2008-08-20 2012-12-04 Baxter International Inc. Methods of processing multi-phasic dispersions
EP2376522A4 (en) * 2008-11-16 2013-12-25 Univ Texas LOW VISCOSIS HIGHLY CONCENTRATED SUSPENSIONS
FR2938542B1 (fr) * 2008-11-18 2013-06-14 Sang Bourgogne Franche Comte Ets Franc Proteine cd20 tronquee, deltacd20
WO2010068866A2 (en) * 2008-12-12 2010-06-17 Bind Biosciences Therapeutic particles suitable for parenteral administration and methods of making and using same
US20100216804A1 (en) * 2008-12-15 2010-08-26 Zale Stephen E Long Circulating Nanoparticles for Sustained Release of Therapeutic Agents
US8529933B2 (en) 2009-07-27 2013-09-10 Warsaw Orthopedic, Inc. Biphasic calcium phosphate cement for drug delivery
JP5491119B2 (ja) 2009-10-02 2014-05-14 日東電工株式会社 薬物含有微粒子を含む医薬組成物およびその製造方法
US8357401B2 (en) 2009-12-11 2013-01-22 Bind Biosciences, Inc. Stable formulations for lyophilizing therapeutic particles
ES2780156T3 (es) 2009-12-15 2020-08-24 Pfizer Composiciones terapéuticas de nanopartículas poliméricas con alta temperatura de transición vítrea o copolímeros de alto peso molecular
US20120309016A1 (en) * 2010-02-11 2012-12-06 Hoffmann-La Roche Inc. 3d adcc nk facs assay
US9643996B2 (en) * 2011-11-04 2017-05-09 Battelle Memorial Institute Processes for producing protein microparticles
PL3574897T3 (pl) 2011-11-18 2022-05-09 Regeneron Pharmaceuticals, Inc. Postać użytkowa o przedłużonym uwalnianiu zawierająca mikrocząstki białka polimerowego do stosowania w ciele szklistym oka w leczeniu naczyniowych zaburzeń oczu
US20150177115A1 (en) 2012-04-06 2015-06-25 Slingshot Biosciences Hydrogel particles with tunable optical properties
ES2729603T3 (es) 2012-06-27 2019-11-05 Merck Sharp & Dohme Anticuerpos IL-23 antihumanos cristalinos
MX356097B (es) 2012-09-17 2018-05-14 Pfizer Inc Star Proceso para la preparacion de nanoparticulas terapeuticas.
JP6026002B2 (ja) * 2012-11-27 2016-11-16 アルテオジェン インコーポレイテッド タンパク質とＦｃドメインを融合した融合タンパク質の安定化用組成物
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
CN103018446B (zh) * 2012-12-24 2014-08-20 青岛汉唐生物科技有限公司 用于检测甲型肝炎病毒抗体的方法、检测用的试剂盒及其制备方法
RU2016111112A (ru) * 2013-08-26 2017-09-29 ПиЭс ТЕРЭПИС ЛТД. Композиции и способы для лечения патологических состояний носа
WO2015058173A1 (en) * 2013-10-18 2015-04-23 Abbvie Inc. Stable solid units and methods of making the same
MA39734B1 (fr) 2014-03-14 2019-07-31 Pfizer Nanoparticules thérapeutiques comportant un agent thérapeutique, et leurs procédés de fabrication et d'utilisation
CN106535928A (zh) 2014-07-18 2017-03-22 般财团法人化学及血清疗法研究所 包含类病毒颗粒的疫苗
JP6910949B2 (ja) * 2014-08-14 2021-07-28 ブラウン ユニバーシティ タンパク質を安定化させ、送達するための組成物
US9821059B2 (en) 2014-10-17 2017-11-21 Alteogen Inc. Composition for stabilizing protein and pharmaceutical formulation comprising the same
EP3256850B1 (en) 2015-02-09 2025-07-09 Slingshot Biosciences, Inc. Hydrogel particles with tunable optical properties and methods for using the same
AR103726A1 (es) 2015-02-27 2017-05-31 Merck Sharp & Dohme Cristales de anticuerpos monoclonales anti-pd-1 humanos
AU2016252393A1 (en) 2015-04-24 2017-11-09 Colgate-Palmolive Company Porous protein particles as carriers for actives
US10281400B2 (en) * 2015-07-13 2019-05-07 Sony Corporation Method for enhancing luminescence, substance detection method, substance detection apparatus, and luminescence enhancer
WO2017219974A1 (zh) 2016-06-22 2017-12-28 本康生物制药（深圳）有限公司 用于肿瘤治疗的双特异性抗体和抗体偶联物及其应用
CN108504638B (zh) * 2017-02-28 2021-09-17 中国科学院过程工程研究所 一种口蹄疫灭活病毒抗原纯化或储存的方法
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
AU2018263868A1 (en) 2017-05-02 2019-12-12 Merck Sharp & Dohme Llc Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies
CN108398550B (zh) * 2018-03-07 2022-07-26 深圳市伯劳特生物制品有限公司 一种组合物、芯片及其制备方法和包含有该芯片的检测装置
KR102885113B1 (ko) 2018-10-18 2025-11-13 머크 샤프 앤드 돔 엘엘씨 항-rsv 항체의 제제 및 그의 사용 방법
CN120842406A (zh) 2018-10-31 2025-10-28 默沙东有限责任公司 抗人pd-1抗体晶体及其使用方法
CN113316458B (zh) 2018-11-07 2024-08-02 默沙东有限责任公司 抗lag3抗体和抗pd-1抗体的共制剂
CN117100683A (zh) * 2018-12-31 2023-11-24 拉尼医疗有限公司 使用可吞服药物递送装置递送到肠道内腔的治疗剂制剂
US10993459B2 (en) 2019-09-23 2021-05-04 Ralph Yoder Method for unlocking bioactive proteins
WO2021108548A1 (en) 2019-11-25 2021-06-03 Regeneron Pharmaceuticals, Inc. Sustained release formulations using non-aqueous emulsions
JP7759328B2 (ja) 2020-01-24 2025-10-23 スリングショット バイオサイエンシーズ， インコーポレイテッド 細胞様較正粒子のための組成物および方法
US20230088835A1 (en) * 2020-03-02 2023-03-23 Northwestern University Fit-flares for detection of intracellular analytes in live cells
CA3177834A1 (en) 2020-05-04 2021-11-11 Jeffrey Kim Compositions and methods for passive optical barcoding for multiplexed assays
WO2022115588A1 (en) 2020-11-25 2022-06-02 Regeneron Pharmaceuticals, Inc. Sustained release formulations using non-aqueous membrane emulsification
JP2024500409A (ja) 2020-12-17 2024-01-09 リジェネロン・ファーマシューティカルズ・インコーポレイテッド タンパク質封入マイクロゲルの作製
JP2024539956A (ja) 2021-10-29 2024-10-31 スリングショット バイオサイエンシーズ， インコーポレイテッド フィーダー細胞としておよび合成抗原提示細胞としてのヒドロゲル粒子
CN114460301B (zh) * 2021-12-28 2024-11-29 上海睿康生物科技有限公司 一种测定血清中肌酸激酶同工酶含量的检测试剂盒
CN119907921A (zh) 2022-05-05 2025-04-29 弹弓生物科学公司 用于血液学的作为红细胞模拟物的工程化颗粒和含有工程化颗粒的组合物
AU2023280490A1 (en) 2022-06-02 2024-12-05 Slingshot Biosciences, Inc. Apoptotic cell mimic
EP4608872A2 (en) 2022-10-26 2025-09-03 Slingshot Biosciences, Inc. Size-tunable synthetic particles with tunable optical properties and methods for using the same for immune cell activation
WO2025049609A1 (en) 2023-08-29 2025-03-06 Slingshot Biosciences, Inc. Cd34 stem cell mimics
CN119925588B (zh) * 2025-04-08 2025-07-01 北京华诺泰生物医药科技有限公司 基于gE/pORF7双抗原纳米晶与智能相变佐剂的重组带状疱疹疫苗

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6063910A (en) * 1991-11-14 2000-05-16 The Trustees Of Princeton University Preparation of protein microparticles by supercritical fluid precipitation

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4334024A (en) 1980-11-03 1982-06-08 Sarjit Johal Preparation and crystallization of fraction I protein from plant sources
DE3327709A1 (de) 1983-07-29 1985-02-07 Hoechst Ag, 6230 Frankfurt Insulin-derivat-kristallsuspensionen, verfahren zu deren herstellung und deren verwendung
DE3419782C1 (de) 1984-05-26 1985-11-14 Gödecke AG, 1000 Berlin Sphaerische Proteinpartikel mit immunadsorbierenden Eigenschaften und Verfahren zu deren Herstellung
US6727278B1 (en) * 1986-08-27 2004-04-27 Dms Pharmaceutical Inc. Pharmaceutically active agents that impede amyloid formation in vivo
WO1991009943A1 (en) 1989-12-21 1991-07-11 Novo Nordisk A/S Method for crystallization of enzymes
US5780599A (en) 1990-07-13 1998-07-14 Novo Nordisk A/S Growth hormone crystals and a process for production of growth hormone crystals
US5618710A (en) 1990-08-03 1997-04-08 Vertex Pharmaceuticals, Inc. Crosslinked enzyme crystals
US5751453A (en) * 1991-12-06 1998-05-12 Ncr Corporation Liquid crystal display with pen-input capability
EP0646000A4 (en) * 1992-11-16 1997-05-02 Univ Mercer COMPOSITIONS CONTAINING MICRO-ENCODED NEUTRALIZING ANTIBODIES.
US6794357B1 (en) * 1993-06-24 2004-09-21 Astrazeneca Ab Compositions for inhalation
US5510118A (en) 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
US5904935A (en) 1995-06-07 1999-05-18 Alza Corporation Peptide/protein suspending formulations
US6143211A (en) * 1995-07-21 2000-11-07 Brown University Foundation Process for preparing microparticles through phase inversion phenomena
JPH11510061A (ja) 1995-08-30 1999-09-07 アリアド・ファーマシューティカルズ・インコーポレイテッド 結晶性ｚａｐファミリータンパク質
US5972331A (en) 1995-12-22 1999-10-26 Schering Corporation Crystalline interferon alpha for pulmonary delivery and method for producing the same
US6652837B1 (en) * 1996-05-24 2003-11-25 Massachusetts Institute Of Technology Preparation of novel particles for inhalation
US5932212A (en) 1996-05-24 1999-08-03 Altus Biologics, Inc. Crosslinked protein crystal formulations and their use as catalysts in organic solvents
US5874064A (en) * 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US6310038B1 (en) 1997-03-20 2001-10-30 Novo Nordisk A/S Pulmonary insulin crystals
US6140475A (en) 1997-04-11 2000-10-31 Altus Biologics Inc. Controlled dissolution crosslinked protein crystals
EP2311436A1 (en) * 1998-04-27 2011-04-20 Altus Pharmaceuticals Inc. Stabilized protein crystals, formulations containing them and methods of making them
US6956021B1 (en) * 1998-08-25 2005-10-18 Advanced Inhalation Research, Inc. Stable spray-dried protein formulations
NZ513163A (en) 1999-03-05 2004-02-27 Genencor Int Method for rapidly obtaining crystals with desirable morphologies
ATE555773T1 (de) * 1999-06-09 2012-05-15 Sievers Robert E Überkritische fluidgestützte verneblung und blasen trochnen
WO2000077281A1 (en) 1999-06-10 2000-12-21 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Encapsulation of crystals via multilayer coatings
GB9915975D0 (en) * 1999-07-07 1999-09-08 Bradford Particle Design Ltd Method for the formation of particles
US6458387B1 (en) * 1999-10-18 2002-10-01 Epic Therapeutics, Inc. Sustained release microspheres
FR2802445B1 (fr) * 1999-12-15 2002-02-15 Separex Sa Procede et dispositif de captage de fines particules par piegeage au sein d'un melange solide de type neige carbonique
US6562952B1 (en) * 2000-10-31 2003-05-13 The University Of Kansas Precipitation of proteins from organic solutions
US6756062B2 (en) * 2000-11-03 2004-06-29 Board Of Regents University Of Texas System Preparation of drug particles using evaporation precipitation into aqueous solutions
EP1801123A3 (en) * 2000-12-28 2007-11-21 Altus Pharmaceuticals Inc. Crystals of whole antibodies and fragments thereof and methods for making and using them
NZ526720A (en) * 2000-12-28 2007-11-30 Altus Pharmaceuticals Inc Crystallisation of whole antibodies or fragments thereof, on a large scale and a process allowing an alternative route for delivery of therapeutic antibodies
CA2451185A1 (en) 2001-06-21 2003-01-03 Altus Biologics, Inc. Spherical protein particles and methods of making and using them
US20060003012A9 (en) * 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6063910A (en) * 1991-11-14 2000-05-16 The Trustees Of Princeton University Preparation of protein microparticles by supercritical fluid precipitation

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Bustami et al. Generation of micro-particles of proteins for aerosol delivery using high pressure modified carbon dioxide. Pharm Res. Nov 2000; vol. 17 no. 11 pages 1360-1366. *
Morita et al. Formation and isolation of spherical fine protein microparticles through lyophilization of protein-poly(ethylene glycol) aqueous mixture. Pharm Res. Nov 2000; vol. 17, no.11, pages 1367-1373. *
Ruth et al. Alpha-L-iduronidase forms semi-crystalline spherulites with amyloid-like properties. Acta Crystallogr D Biol Crystallogr. April 2000; vol. 56 Pt 4 pages 524-528. *

Also Published As

Publication number Publication date
EP1492554B1 (en) 2019-08-21
WO2003000014A2 (en) 2003-01-03
AU2002322295B2 (en) 2008-07-03
IL159475A0 (en) 2004-06-01
CA2451185A1 (en) 2003-01-03
WO2003000014A3 (en) 2004-10-21
NZ530700A (en) 2009-02-28
JP2005500304A (ja) 2005-01-06
US20120282464A1 (en) 2012-11-08
US20040219224A1 (en) 2004-11-04
EP1492554A4 (en) 2012-07-11
US7998477B2 (en) 2011-08-16
EP1492554A2 (en) 2005-01-05

Similar Documents

Publication Publication Date Title
AU2002322295C1 (en) Spherical protein particles and methods of making and using them
AU2002322295A1 (en) Spherical protein particles and methods of making and using them
JP4731793B2 (ja) 抗体全体またはそのフラグメントの結晶、ならびにこの結晶を作製および使用するための方法
AU2002256971A1 (en) Crystals of whole antibodies and fragments thereof and methods for making and using them
US8940873B2 (en) Crystalline anti-human IL-12 antibodies
CN102753570B (zh) A蛋白晶体和交联晶体及其使用方法
JP2006514954A (ja) 抗体含有粒子及び組成物
CN103517920A (zh) 抗硬化蛋白(sclerostin)抗体晶体及其制剂
EP1801123A2 (en) Crystals of whole antibodies and fragments thereof and methods for making and using them
SK286627B6 (sk) Použitie protilátok na vakcináciu proti nádorovýmochoreniam
AU2008201480A1 (en) Crystals of Whole Antibodies and Fragments Thereof and Methods for Making and Using Them
WO1998057661A1 (en) Therapeutic composition and method of treatment
HK1105648A (en) Crystals of whole antibodies and fragments thereof and methods for making and using them
HK1179270A (en) Crystalline anti-human il-12 antibodies
HK1129400B (en) Crystalline anti-htnfalpha antibodies
HK1129400A1 (en) Crystalline anti-htnfalpha antibodies

Legal Events

Date Code Title Description
TC Change of applicant's name (sec. 104)

Owner name: ALTUS PHARMACEUTICALS INC.

Free format text: FORMER NAME: ALTUS BIOLOGICS INC

DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 15 JUL 2008.

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired